VxP Pharma announces launch of VxP Biologics, Inc. focusing on the Contract Development & cGMP Manufacturing of Biologics for Clinical Trials at it's US-FDA Audited Sites

Friday, April 22, 2016 General News J E 4
VxP Biologics Inc. provides comprehensive contract development and cGMP manufacturing of biologics at its US-FDA audited facilities in the United States as well as at its US-FDA audited cGMP facility in India. Service areas include biologics process development and manufacturing recombinant DNA engineering cell line development protein sciences (purification and crystallography) in-vivo pharmacology and toxicology as well as cGMP antibody generation. All VxP facilities are US-FDA audited and are currently serving the global pharmaceutical and biotech industry. VxP Pharma was founded in 2010 as CRO Solutions Inc. a sales representation agency representing global Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) from a business development and marketing standpoint. VxP Pharma was launched in 2014 as a platform to promote the combined services of all CRO Solutions clients under a single brand. VxP offers its services to research and development scientists at pharma and biotech companies worldwide and has a staff of full-time business development representatives covering all major markets as well as inside sales technical support internet marketing and operations support. VxP Pharma CEO Raymond E Peck says “The VxP Pharma platform has been extremely successful both for us and for our global clients. Biologics has become a growing part of our portfolio so we feel that the creation of VxP Biologics is a natural extension of our service offering and of our VxP brand.” VxP is headquartered in Indianapolis Indiana. To find out more please visit:


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
TKCI Lays Out its Plan to Control Corneal Blindnes...
International Survey Released for World Meningitis...